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Human immunodeﬁciency virus type 1 (HIV-1) evades CD8
 T-cell responses through mutations within
targeted epitopes, but little is known regarding its ability to generate de novo CD8
 T-cell responses to such
mutants. Here we examined gamma interferon-positive, HIV-1-speciﬁc CD8
 T-cell responses and autologous
viral sequences in an HIV-1-infected individual for more than 6 years following acute infection. Fourteen
optimal HIV-1 T-cell epitopes were targeted by CD8
 T cells, four of which underwent mutation associated with
dramatic loss of the original CD8
 response. However, following the G357S escape in the HLA-A11-restricted
Gag349–359 epitope and the decline of wild-type-speciﬁc CD8
 T-cell responses, a novel CD8
 T-cell response
equal in magnitude to the original response was generated against the variant epitope. CD8
 T cells targeting
the variant epitope did not exhibit cross-reactivity against the wild-type epitope but rather utilized a distinct
T-cell receptor V repertoire. Additional studies of chronically HIV-1-infected individuals expressing HLA-A11
demonstrated that the majority of the subjects targeted the G357S escape variant of the Gag349–359 epitope,
while the wild-type consensus sequence was signiﬁcantly less frequently recognized. These data demonstrate
that de novo responses against escape variants of CD8
 T-cell epitopes can be generated in chronic HIV-1
infection and provide the rationale for developing vaccines to induce CD8
 T-cell responses directed against
both the wild-type and variant forms of CD8 epitopes to prevent the emergence of cytotoxic T-lymphocyte
escape variants.
Virus-speciﬁc CD8
 T-cell responses have been shown to
play an important role in the control of many viral infections,
including human immunodeﬁciency virus type 1 (HIV-1) in-
fection. CD8
 T cells recognize viral antigens (epitopes) pre-
sented by HLA class I molecules on the surface of infected
cells through speciﬁc binding of their T-cell receptor (TCR)
with the HLA class I-epitope complex. A number of studies
have demonstrated that viruses can evade CD8
 T-cell-medi-
ated immune pressure through the selection of sequence vari-
ations within targeted regions (5, 23, 24, 29, 32). Studies of
HIV-1 and simian immunodeﬁciency virus (SIV) infections
have shown selection of cytotoxic T-lymphocyte (CTL) escape
variants during both primary and chronic infections (1, 2, 6,
10–12, 16, 20, 21, 26, 37, 40, 42). A subset of studies has
furthermore demonstrated that the selection of viral escape
variants during chronic SIV and HIV-1 infections can result in
loss of immune control and disease progression (6, 14, 21).
Thus, the ability of HIV-1 to escape from virus-speciﬁc CD8

T-cell responses has been proposed as an important obstacle
for the maintenance of protective immune responses (5, 24,
32), and likewise the viral diversity resulting from CTL-driven
viral evolution represents a major hurdle for HIV-1 vaccine
design (47).
Viral escape from CD8
 T-cell-mediated immune pressure
predominantly occurs through the selection of sequence vari-
ations in positions within targeted CD8
 T-cell epitopes that
are crucial for the binding to HLA class I molecules (anchor
positions) (1, 11) or positions that are responsible for the
interaction between the TCR and the peptide-HLA class I
complex (TCR sites). Both mechanisms result in the loss of
recognition of the variant form of the epitope. More recently,
the extent to which mutations both within targeted CD8

T-cell epitopes and within regions ﬂanking these epitopes can
impair processing of the respective epitope (1, 11, 48) is be-
coming better understood. As a consequence, both processing
mutations and mutations within HLA-binding anchor residues
of CD8
 T-cell epitopes have the capacity to impair the rec-
ognition of infected cells by all epitope-speciﬁc CD8
 T cells,
irrespective of their TCR usage. In contrast, amino acid
changes in positions of a CD8
 T-cell epitope that are respon-
* Corresponding author. Mailing address: Partners AIDS Research
Center, Massachusetts General Hospital, 149 13th Street, Boston, MA
02129. Phone: (617) 724-2461. Fax: (617) 724-8586. E-mail: maltfeld
@partners.org.
† T.M.A. and X.G.Y. contributed equally to this study.
12952
 
o
n
 
M
a
y
 
1
,
 
2
0
1
3
 
b
y
 
S
U
B
 
N
O
.
6
3
7
4
5
2
9
1
h
t
t
p
:
/
/
j
v
i
.
a
s
m
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 sible for the interaction with the TCR allow for the continuous
presentation of the epitope on the surface of infected cells.
This persistent presentation of the viral epitope variants on
infected cells may therefore enable the recruitment of novel
epitope-speciﬁc CD8
 T cells utilizing the TCR that are capa-
ble of recognizing the variant epitope.
Here, we studied the evolution of HIV-1-speciﬁc CD8
 T-
cell responses and autologous viral sequences in an infected
individual identiﬁed during acute HIV-1 infection to deter-
mine whether following viral escape CD8
 T-cell responses
are capable of recognizing the escaped CTL epitope. We ob-
served viral escape from CTL-mediated immune pressure in
multiple targeted epitopes, which was followed by a dramatic
decline in the respective epitope-speciﬁc CD8
 T-cell re-
sponses. However, following the selection of a G357S CTL
escape variant in an HLA-A11-restricted CD8
 T-cell epitope
within HIV-1 p24 Gag349–359 (ACQGVGGPGHK) and the
decline of wild-type-speciﬁc CD8
 T-cell responses, a new
CD8
 T-cell response equal in magnitude to the original T-cell
response did develop that was speciﬁc for the G357S CTL
escape variant and did not cross-react with the wild-type
epitope. These data demonstrate that de novo epitope-speciﬁc
CD8
 T-cell responses directed against CTL escape variants
can be generated in chronic adult HIV-1 infection and indicate
that vaccine strategies aiming to induce CD8
 T-cell responses
directed against both the wild-type epitope and the CTL es-
cape variant of an epitope should be possible in order to help
prevent the emergence of CTL escape variants.
MATERIALS AND METHODS
Study subjects. A total of 14 individuals followed at the Partners AIDS Re-
search Center at Massachusetts General Hospital in Boston were enrolled in this
study. All individuals expressed the HLA class I allele HLA-A11. Study subjects
included subject AC-04, who was identiﬁed during acute HIV-1 infection, prior
to HIV-1 seroconversion (27, 45), and 13 individuals identiﬁed during chronic
infection. Chronically infected individuals were infected for more than 2 years.
The study was approved by the institutional review board and was conducted in
accordance with the human experimentation guidelines of the Massachusetts
General Hospital.
IFN- ELISPOT assay. HIV-1-speciﬁc CD8
 T-cell responses were quantiﬁed
by gamma interferon (IFN-) enzyme-linked immunospot (ELISPOT) assay (4)
using overlapping peptides spanning the HIV-1 clade B consensus sequence (15)
and a panel of peptides corresponding to previously described optimal clade B
CTL epitopes (9). Peripheral blood mononuclear cells (PBMC) were plated at
100,000 per well with peptides at a ﬁnal concentration of 14 g/ml in 96-well
plates and processed as previously described (4). PBMC were incubated with
medium alone (negative control) and phytohemagglutinin (positive control).
Speciﬁc IFN--secreting T cells were counted using an automated ELISPOT
reader (AID, Strassburg, Germany) and calculated by subtracting the average
negative control value and expressed as the number of spot-forming cells (SFC)
per 10
6 input cells. Negative controls were always 30 SFC per 10
6 input cells.
A response was considered positive if 50 SFC per 10
6 input cells and at least
three times greater than the mean background activity. Comparisons of recog-
nition of epitope variants were performed by ELISPOT assay using serial dilu-
tions of truncated peptides as previously described (3).
Analysis of HIV-1-speciﬁc CD8
 T-cell function by multiparameter ﬂow cy-
tometry. HLA-A11 peptide tetramers refolded with epitopic peptides corre-
sponding to the wild-type sequence of the HIV-1 p24 Gag349–359 CD8
 T-cell
epitope ACQGVGGPGHK and the G357S variant of this epitope ACQGVGG
PSHK (the difference is underlined) were purchased from a commercial supplier
(Beckman Coulter) with phycoerythrin (PE) or allophycocyanin (APC) ﬂuores-
cence conjugation, respectively. Five hundred thousand to 1 million cells were
initially incubated with A11-tetramer complexes (Beckman Coulter, San Diego,
CA) refolded with the wild-type peptide or the mutant AK11G357S peptide for 30
min at room temperature as described previously (22). After two washes with
phosphate-buffered saline, the wild-type or mutant A11-AK11 peptide (2 g/ml)
was added together with anti-CD28 antibodies, anti-CD49d antibodies (1 g/ml
each; BD Biosciences, San Jose, CA), and PE-Cy5-labeled CD107a antibodies
(10 l/ml; BD Biosciences). Brefeldin A (10 g/ml; Sigma) and monensin (6
g/ml; BD Biosciences) were added after the initial hour of incubation. After an
additional5ho fincubation, cells were washed with phosphate-buffered sa-
line–1% bovine serum albumin and stained with surface antibodies (CD8 APC-
Cy7, CD3 APC-Cy5.5, CD45RA Alexa Fluor 405, and CCR7 PE-Cy7). Cells
were then washed again, ﬁxed, and permeabilized using the Caltag Fixation-
Permeabilization kit (Caltag, Burlingame, CA) and stained for intracellular ex-
pression of cytokines (interleukin-2–PE and IFN-–ﬂuorescein isothiocyanate).
In a subset of experiments, PBMC were only incubated with both the A11
tetramers refolded with the wild-type epitope peptide and the escape variant
peptide and anti-CD8 and anti-CD4. Cells were acquired on an LSRII ﬂow
cytometer (BD Biosciences) using the FACSDiVa software. Control conditions
were established by the use of autologous PBMC which had not been stimulated
with peptide but otherwise had been treated identically. Flow data were analyzed
with the FlowJo software package (Treestar, Ashland, OR).
Characterization of TCR V chain usage of epitope-speciﬁc CD8
 T cells.
Epitope-speciﬁc CD8
 T cells were identiﬁed by intracellular cytokine staining
as described above, using anti-CD8 and anti-IFN- monoclonal antibodies (Bec-
ton Dickinson), and also stained with a panel of 24 ﬂuorescein isothiocyanate- or
PE-conjugated monoclonal antibodies against TCR V chains (Beckman
Coulter) most frequently used by CD8
 T cells and processed as described
above. A speciﬁc TCR V chain usage was deﬁned when more than 2% of the
epitope-speciﬁc CD8
 T cells were stained positive with the respective TCR V
chain antibody.
Sequencing of autologous virus. Autologous virus was sequenced from plasma
RNA using population and clonal sequencing as described previously (3). Viral
RNA was isolated from plasma, and a nested PCR was conducted using a set of
described primers speciﬁc for HIV-1 (3). First-round PCR cycling conditions
were 94°C for 2 min; 35 to 50 cycles of 30 s at 94°C, 30 s at 56°C, and 2 min at
72°C; and a ﬁnal extension of 68°C for 20 min, and nested PCRs were shortened
to a 1-min extension time. PCR fragments were then gel puriﬁed and sequenced
directly or cloned (TOPO TA Cloning kit; Invitrogen, Carlsbad, CA). Plasmid
DNA was isolated by miniprep (QiaPrep Turbo Miniprep) and sequenced bidi-
rectionally on an ABI 3100 PRISM automated sequencer. Sequencher (Gene
Codes Corp., Ann Arbor, MI) and MacVector 4.1 (Oxford Molecular) were used
to edit and align sequences.
Assessment of statistically signiﬁcant associations between viral sequences
and HLA class I alleles. The autologous (pretreatment) HIV-1 sequences from
230 individuals in the Western Australian HIV Cohort Study (35) were examined
in the segments within speciﬁed CD8
 T-cell epitopes targeted by study subject
AC-04. Bulk sequencing of plasma RNA was performed using previously de-
scribed methods (38). HLA-A, -B, and -C genotypes were also determined for all
individuals by standard sequence-based genotyping. Each individual in the pop-
ulation therefore contributed a single HIV-1 sequence and an HLA class I
genotype to the analysis. Statistical associations between viral sequences and
HLA class I genotypes were examined using the Epipop program as previously
described (35). Multivariate logistic regression models were carried out for each
viral position of interest with the outcome set as a speciﬁed amino acid and the
HLA-A, -B, and -C genotypes as covariates, generating an odds ratio and a P
value for each HLA allele-viral sequence association.
Statistical analysis. Statistical analysis and graphical presentation were done
using SigmaPlot 5.0 (SPSS Inc., Chicago, IL). Results are given as a mean  a
standard deviation or a median with a range. Statistical analysis of signiﬁcance (P
values) was based on two-tailed t tests and Fischer’s exact test.
Nucleotide sequence accession numbers. The sequence data determined in
this study were submitted to GenBank and assigned accession no. DQ127534 to
DQ127536 and DQ127172 to DQ127224.
RESULTS
Evolution of viral sequence variations within targeted CD8

T-cell epitopes. Viral escape from CTL responses has been
shown to be a hallmark of SIV and HIV-1 infections (1, 2, 6,
10–12, 16, 20, 21, 26, 37, 40, 42). In order to better understand
the impact of viral sequence variations within targeted CD8

T-cell epitopes on the evolution of epitope-speciﬁc CD8
 T-
cell responses, we performed detailed longitudinal studies of
HIV-1-speciﬁc T-cell responses and autologous viral se-
VOL. 79, 2005 DE NOVO RESPONSES AGAINST CTL ESCAPE VARIANT 12953
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 quences in an infected individual identiﬁed during acute
HIV-1 infection. This study subject (AC-04) presented during
symptomatic acute infection with a negative HIV-1 p24 Gag
enzyme-linked immunosorbent assay, a viral load of 10  10
6
copies of HIV-1 RNA per ml of plasma, and a CD4
 T-cell
count of 652 cells per l (27, 45). The study subject was treated
with highly active antiretroviral therapy (HAART) within 7
days of presentation, and the viral load was suppressed below
the limit of detection within 286 days. After 617 days of suc-
cessful treatment (day 624 postpresentation [pp]), AC-04 un-
derwent four cycles of structured treatment interruptions (Fig.
1). The viral load rebounded during each treatment interrup-
tion, resulting in a continuous decline in CD4
 T cells during
the periods of viral replication, reaching 237 CD4
 T cells per
l at day 2,240 pp, when HAART was reinitiated.
HIV-1-speciﬁc CD8
 T-cell responses in subject AC-04
were assessed using an IFN- ELISPOT assay and peptides
corresponding to optimal CTL epitopes described for the in-
dividual’s HLA class I type (A2, A11, B18, B44, Cw5, and
Cw12). Over the 2,400-day study period, including 1,410 days
on HAART and 990 days off HAART, AC-04 developed T-cell
responses to 14 described optimal CD8
 T-cell epitopes (Ta-
ble 1). In addition, comprehensive assessment of CD8
 T-cell
responses using overlapping peptides spanning the entire
HIV-1 clade B consensus sequence identiﬁed eight additional
CD8
 T-cell responses against epitopes not yet optimally de-
ﬁned (data not shown). Sequencing of the autologous virus
during primary infection (55 days pp), as well as 2,227 days pp,
demonstrated sequence evolution within 4 of the 14 optimal
CD8
 T-cell epitopes targeted (Table 1). In each case, viral
sequence evolution within these four targeted epitopes re-
sulted in an in vivo decline of CD8
 T-cell responses directed
against peptides corresponding to the respective wild-type se-
quence (Fig. 2). In order to examine in vitro the impact of
these variant epitopes on CD8
 T-cell recognition, the pep-
tides corresponding to the escape variants of the respective
epitopes were tested for recognition using PBMC. In three out
of the four cases, the variant epitopes were not recognized by
early wild-type-speciﬁc CD8
 T-cell responses (Fig. 2A to C),
while signiﬁcant cross-recognition existed between the wild-
type and escape variant peptides of the HLA-Cw12-restricted
Tat epitope when maximal peptide concentrations were used
in the ELISPOT assay (Fig. 2D). In this case, however, the use
of serial peptide dilutions of the wild-type and escape variant
FIG. 1. Clinical course of HIV-1 infection in study subject AC-04. Viral loads and CD4
 T-cell counts in AC-04 are shown, starting at the time
of acute HIV-1 infection. Shaded regions denote time under treatment with HAART.
TABLE 1. HIV-1-speciﬁc CD8
 T-cell epitopes targeted
in subject AC-04
Epitope Peptide
sequence
No. of
SFC/10
6
PBMC
a
Sequence
variation
b
A11-AK11 Gag349–359 ACQGVGGPGHK 1,280 ACQGVGGPGHK
--------S--
A2-AL9 Vpr59–67 ALIRILQQL 950 ALIRILQQL
--t-S----
c
Cw12-CC8 Tat30–37 CCFHCQVC 750 CCFHCQVC
--M-----
Cw5-SL9 Rev67–75 SAEPVPLQL 1,000 SAEPVPLQL
----G----
B44-AW11 Gag306–316 AEQASQDVKNW 2,310 None
A11-AK9 Pol314–322 AIFQSSMTK 640 None
A11-QK9 Pol425–433 QIYAGIKVK 530 None
A11-IK10 Pol497–506 IYQEPFKNLK 730 None
A11-QK9 Pol676–684 QIIEQLIKK 320 None
B18-LY10 Vif102–110 LADQLIHLHY 1,930 None
A11-QK10 Nef73–82 QVPLRPMTYK 820 None
A11-AK9 Nef84–92 AVDLSHFLK 2,129 None
B18-YY9 Nef135–143 YPLTFGWCY 240 None
A2-LV10 Nef137–146 LTFGWCFKLV 250 None
a Peak epitope-speciﬁc IFN- CD8
 T-cell responses (SFC/10
6 PBMC).
b Autologous viral sequences during primary infection (day 55 pp) and day
2,227 pp. Dashes indicate parts of sequences that match those of the lines above.
c A lowercase letter indicates a mixed-based population at that residue.
12954 ALLEN ET AL. J. VIROL.
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 peptides demonstrated that the wild-type peptide was recog-
nized at 100-fold lower concentrations (data not shown), sug-
gesting that the sequence variations also resulted in reduced
recognition of this epitope. Taken together, these data dem-
onstrate the development of robust, HIV-1-speciﬁc CD8
 T-
cell responses in subject AC-04 that resulted in viral escape
from CTL-meditated immune pressure in 4 out of the 14 op-
timal CD8
 T-cell epitopes targeted and a decline in the fre-
quency of each wild-type-speciﬁc CD8
 T-cell response.
Development of de novo CD8
 T-cell responses directed
against a CD8 T-cell viral escape variant. We observed that
none of the sequence variations in the four escaping CD8

T-cell epitopes in subject AC-04 occurred within HLA binding
anchor positions that would likely prevent the epitope from
reaching the cell surface, but rather within amino acid posi-
tions potentially responsible for the interaction with the TCR
of the respective CD8
 T cells (9, 13, 34, 44). This prompted
us to follow the evolution of CD8
 T-cell responses to these
escape variants longitudinally in order to determine whether
new CD8
 T-cell responses developed that were capable of
recognizing the variant epitopes. While CD8
 T-cell responses
to the Rev, Tat, and Vpr epitopes continuously declined fol-
lowing the development of the escape mutations, a new CD8

T-cell response speciﬁc to the G357S escape variant of the
HLA-A11-restricted p24 Gag349–359 epitope (ACQGVGG
PSHK [the variation is underlined]; A11-AK11G357S) emerged
at day 1,471 (Fig. 2A), approximately 674 days following the
ﬁrst detection of autologous virus harboring the p24 Gag G357S
mutation (Table 2). This A11-AK11G357S-speciﬁc CD8
 T-cell
response subsequently increased in frequency, reaching 1,400
SFC/10
6 PBMC at day 2,164 pp (Fig. 2A), at a time when 100%
of the cloned sequence harbored the p24 Gag G357S mutation
(Table 2). Interestingly, this novel CD8
 T-cell response was
speciﬁc for the A11-AK11G357S escape variant but did not
demonstrate signiﬁcant cross-reactivity with the A11-AK11
wild-type sequence (Fig. 2A). This lack of detectable cross-
reactivity of the novel variant-speciﬁc CD8
 T-cell response
with the wild-type sequence was reconﬁrmed using HLA-A11
tetramers refolded with either the wild-type A11-AK11 pep-
tide or the A11-AK11G357S escape variant peptide. While
CD8
 T cells isolated at day 1,427, at the peak response
against the wild-type epitope, only bound to HLA-A11 tetram-
ers refolded with the wild-type epitope, CD8
 T cells derived
from day 2,323 only bound the HLA-A11 tetramer refolded
with the A11-AK11G357S escape variant peptide (Fig. 3).
Taken together, these data demonstrate the development of
FIG. 2. Changes in epitope-speciﬁc CD8
 T-cell responses in relationship to the emergence of viral sequence variations in AC-04. Changes in
the magnitude of epitope-speciﬁc CD8
 T-cell responses measured by IFN- ELISPOT assay are shown for the four epitopes targeted by study
subject AC-04 that exhibited viral sequence variations over time. Panels: A, HIV-1 Gag349–359; B, HIV-1 Rev67–75; C, HIV-1 Vpr57–63; D, HIV-1
Tat30–37. Shaded regions denote periods during which the autologous viral sequence reﬂected wild-type (wt) sequences, escape variant sequences,
or a mixture of both, as determined by the sequencing of individual viral clones. Mill, million.
VOL. 79, 2005 DE NOVO RESPONSES AGAINST CTL ESCAPE VARIANT 12955
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 novel CD8
 T-cell responses speciﬁc for the CTL escape vari-
ant of the A11-AK11 epitope that do not cross-react with the
original wild-type sequence.
De novo CD8
 T-cell responses directed against the A11-
AK11G357S escape variant use a distinct TCR V repertoire
but exhibit similar functional properties. To further investi-
gate the differences between the original wild-type (A11-
AK11)-speciﬁc CD8
 T-cell responses and the de novo re-
sponses directed against the escape variant (A11-AK11G357S),
we used TCR V-speciﬁc antibodies to characterize the TCR
usage of the A11-AK11- and A11-AK11G357S-speciﬁc CD8
 T
cells. While 82% of the A11-AK11-speciﬁc CD8
 T cells iden-
tiﬁed by IFN- production following stimulation with the A11-
AK11 wild-type peptide used TCR V1, A11-AK11G357S-spe-
ciﬁc CD8
 T cells did not stain with the TCR V1 antibody
(1.7%) but rather with a TCR V9-speciﬁc antibody (31%)
(Fig. 4). These data demonstrate that study subject AC-04
recruited a new subset of CD8
 T cells speciﬁc for the CTL
escape variant that did not cross-react with the original wild-
type sequence and utilized TCRs expressing a different V
chain.
We subsequently used multiparameter ﬂow analysis to char-
acterize the functional properties of the A11-AK11-speciﬁc
CD8
 T-cell responses primed during primary HIV-1 infection
and the A11-AK11G357S-speciﬁc responses generated during
chronic infection. As described previously (19, 22), only a sub-
set of the tetramer-positive CD8
 T cells produced IFN-
following stimulation with the respective epitopic peptide
(10.8% of the A11-AK11-speciﬁc CD8
 T cells on day 839 pp
and 20.9% of the A11-AK11G357S-speciﬁc CD8
 T cells at day
2,010). Similarly, only 10.9% and 33.5% of the A11-AK11-
speciﬁc and A11-AK11G357S-speciﬁc CD8
 T cells, respec-
tively, expressed the degranulation maker CD107a following
stimulation. Overall, tetramer-speciﬁc CD8
 T cells were pre-
dominantly of a CCR7
neg CCD45RA
neg effector memory phe-
notype (88.2% for the A11-AK11-speciﬁc and 87.1% for the
A11-AK11G357S-speciﬁc CD8
 T cells), while 6.6% and 7.8%,
respectively, expressed markers characteristic for terminally
differentiated effector cells (CCR7
neg CD45RA
pos). Taken to-
gether, these data suggest that the de novo CD8
 T-cell re-
sponses speciﬁc for the escape variant (A11-AK11G357S), and
arising during chronic infection, did not differ signiﬁcantly in
their function from wild-type-speciﬁc CD8
 T cells with the
assays described.
The A11-AK11G357S variant epitope is frequently recognized
during chronic infection. The above data demonstrate that de
novo responses to the G357S escape variant of the HLA-A11-
restricted p24 Gag349–359 CD8
 T-cell epitope can be gener-
ated in natural HIV-1 infection. An analysis of 101 HIV-1
clade B sequences published in the Los Alamos HIV-1 data-
base demonstrated that while positions P1 to P8 and P10 to
P11 of the A11-AK11 epitope were highly conserved in these
sequences (99%), suggesting functional constraints in this re-
gion of p24, at position 9, where the mutation arose in AC-04,
serine (S) represented a common polymorphism (25%) (Table
3). An analysis of statistical associations between viral se-
quences and HLA class I genotypes in the Western Australian
HIV Cohort Study using the Epipop program (35) demon-
strated that this G357S mutation was signiﬁcantly associated
with the expression of HLA-A11 in HIV-1-infected individuals
(55% of sequences; odds ratio  3.7; P  0.004).
Because these data suggested that the G357S mutation
evolves frequently in chronically HIV-1-infected individuals
expressing HLA-A11, we next examined the frequency by
which the A11-AK11G357S escape variant peptide was recog-
nized by CD8
 T cells from chronically HIV-1-infected indi-
viduals expressing HLA-A11. Of 13 chronically HIV-1-infected
individuals tested expressing HLA-A11, 5 had no detectable
responses against either the A11-AK11 wild-type peptide or
the A11-AK11G357S escape variant peptide. Surprisingly, the
remaining eight subjects all had detectable CD8
 T-cell re-
sponses directed against the nonconsensus A11-AK11G357S
variant form of the epitope, ranging from 100 to 900 SFC/10
6
PBMC (median, 170 SFC/10
6 PBMC), with two of these sub-
jects exhibiting at the same time responses directed against the
A11-AK11 wild-type peptide of 50 and 640 SFC/10
6 PBMC,
respectively (P  0.03). Sequence data for the autologous virus
were available for 8 of the 13 subjects (data not shown). In only
one case was the wild-type sequence of the A11-AK11 epitope
detected, while the A11-AK11G357S escape variant sequence
FIG. 3. Lack of cross-reactivity between A11-AK11-speciﬁc and
A11-AK11G357S-speciﬁc CD8
 T cells. Dot plots showing the ﬂow
cytometric analysis of HIV-1-speciﬁc CD8
 T-cell responses in AC-04
using MHC class I-peptide tetramer complexes speciﬁc for the A11-
AK11 peptide (PE labeled) or for the A11-AK11G357S escape variant
(APC labeled). Tetramer-positive CD8
 T cells were quantiﬁed at day
1,427 pp and day 2,323 pp. wt, wild type.
TABLE 2. Population and clonal p24 Gag349–359
sequences in subject AC-04
Days
pp Population sequence Clonal sequence Clonal
frequency
%G 357S
variant
ACQGVGGPGHK ACQGVGGPGHK
55 ----------- ND
a ND ND
660 ----------- ND ND ND
797 --------S-- ----------- 4/18 78
--------S-- 14/18
930 --------S-- ----------- 7/12 42
--------S-- 5/12
1,670 --------S-- ----------- 0/12 100
--------S-- 12/12
2,227 --------S-- ----------- 0/11 100
--------S-- 10/11
-----W--S-- 1/11
a ND, not done.
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 was present in ﬁve subjects and a glycine-to-alanine substitu-
tion was present in position p24 Gag357 in the remaining two
subjects. Three out of the ﬁve subjects with the A11-
AK11G357S escape variant had mounted a detectable A11-
AK11G357S-speciﬁc CD8
 T-cell response. Interestingly, in the
two subjects exhibiting the rare A11-AK11G357A variant (Table
3), no or only very weak (100 SFC/10
6 PBMC) CD8
 T-cell
responses were detectable against the A11-AK11 wild-type and
A11-AK11G357S escape variant peptides, potentially suggesting
further evolution of the virus away from the variant-speciﬁc
response. Taken together, these data suggest that the G357S
mutation occurs frequently in HIV-1-infected individuals ex-
pressing HLA-A11, resulting in signiﬁcantly more frequent
recognition of the A11-AK11G357S escape variant than the
wild-type sequence in individuals with chronic HIV-1 infection.
DISCUSSION
A number of recent studies have demonstrated that viral
escape from CTL-mediated immune pressure occurs fre-
quently in HIV-1 and SIV infections (1, 2, 6, 10–12, 16, 20, 21,
26, 37, 40, 42) and can be associated with the loss of vaccine-
induced protection from disease progression (6). However,
little is known about the ability of the immune system to
respond to viral escape by developing novel CD8
 T-cell re-
sponses against these CTL escape variants. Here we demon-
strate that de novo CD8
 T-cell responses restricted by the
same HLA class I allele can be generated against HIV-1 CTL
escape variants harboring sequence variations within residues
that determine TCR binding. This observation is relevant for
vaccine design, as immunization with both the wild-type se-
FIG. 4. Usage of different TCR V repertoires by A11-AK11-speciﬁc and A11-AK11G357S-speciﬁc CD8
 T cells. A11-AK11- and A11-
AK11G357S-speciﬁc CD8
 T cells were characterized by intracellular IFN- staining following stimulation with the respective peptide at day 1,427
pp (A) and day 2,220 pp (B). TCR V usage was determined using V-speciﬁc antibodies. At day 1,427 pp (A), only A11-AK11 (wild type
[wt])-speciﬁc CD8
 T cells were detectable, while at day 2,220 pp (B), only A11-AK11G357S (escape variant)-speciﬁc CD8
 T-cell responses were
detectable. A11-AK11-speciﬁc CD8
 T cells utilized TCR V1 (82.4%), while A11-AK11G357S-speciﬁc CD8
 T cells did not utilize TCR V1
(1.7%) but rather TCR V9 (30.5%). FITC, ﬂuorescein isothiocyanate.
TABLE 3. Sequence variability within HIV-1 clade B Gag349–359
Sequence Frequency Percentage
ACQGVGGPGHK 71/101 70
--------S-- 24/101 24
--------A-- 2/101 2
---E----S-- 1/101 1
--------H-- 1/101 1
----G------ 1/101 1
-----E--A-- 1/101 1
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 quence and the predictable CTL escape variant of the respec-
tive epitopes may be able to restrict the ability of the virus to
evade virus-speciﬁc CD8
 T-cell responses through sequence
variation.
Here we demonstrate that the immune system is capable of
mounting novel CD8
 T-cell responses against CTL escape
variants that affect TCR recognition, using epitope-speciﬁc
CD8
 T cells expressing a different TCR repertoire. Our data
are in line with previous reports that HIV-1-speciﬁc CD8

T-cell responses can adapt to viral evolution (25) but demon-
strate for the ﬁrst time convincingly, providing data on the
TCR repertoire used, development of de novo CD8
 T-cell
responses speciﬁc for the escape variant epitope. These data
demonstrating the ability to generate de novo CD8
 T-cell
responses to escape variants are in partial contrast to a recently
published observation in the SIV macaque model describing
the poor recognition of CD8
 T-cell escape mutations by
CD8
 T-cell responses in naive hosts (18). In this study, how-
ever, the three SIV CTL epitopes investigated exhibited se-
quence variations within positions important for the binding of
the epitope to the respective MHC class I molecules (C-ter-
minal anchor in one epitope and secondary anchors in the
remaining two epitopes), and each of the mutant peptides
showed at least a 90% reduction in binding to MHC class I
(18). These mutations in residues impacting the presentation
by MHC class I most likely explain the inability of these three
epitope variants to prime de novo responses in a naive host. In
contrast, the HIV-1 p24 Gag G357S mutation studied here
represented a mutation in a residue responsible for the inter-
action with the TCR (34) and was able to recruit novel CD8

T cells utilizing a different TCR V chain. These data demon-
strate that the impact of a CTL escape mutation on recognition
by CD8
 T cells depends on the position of the mutated
residue within the epitope and that mutations within residues
responsible for the interaction with the TCR may enable the
immune system to mount novel CD8
 T-cell responses against
these variant epitopes.
Why is the virus not mutating exclusively at residues that
entirely abolish the presentation of the targeted epitope, as this
would provide a stronger selection advantage? A number of
recent studies have demonstrated that the variability of HIV-1
is not unlimited but restricted by functional or structural con-
straints (7, 16, 17, 28, 39, 41). Indeed, the analysis of HIV-1
clade B sequences published in the Los Alamos HIV-1 Data-
base demonstrated that most of the positions within the HLA-
A11-restricted p24 Gag epitope AK11 are highly (99%) con-
served, and only position 9 (HIV-1 Gag357) exhibited some
degree of sequence variability that was predominantly re-
stricted to two amino acids, glycine and serine. This observa-
tion suggests that viral sequence evolution within the p24 Gag
epitope A11-AK11 is restricted, forcing the virus to evolve
toward residues that may not represent the most effective sub-
stitution for immune escape. Such CD8
 T-cell epitopes,
which are limited in their capacity to escape and to which the
immune system is reproducibly capable of recognizing the es-
caped form of the virus, may represent attractive targets for
vaccines.
The ability of the escape variant containing the G357Sm u -
tation to induce strong epitope-speciﬁc CD8
 T-cell responses
also indicates that original antigenic sin, that has been pro-
posed to limit the ability of the immune system to generate new
responses to escape variants (33), can be overcome in the
setting of this CD8
 T-cell epitope. It has been demonstrated
that some variant CD8
 T-cell epitopes can function as TCR
antagonists, limiting the capacity of the immune system to
generate novel responses to the escaped epitope (30, 31, 43).
The ability of the immune system to generate de novo re-
sponses against the G357S escape variant epitope may be
largely due to the apparent lack of cross-recognition between
CD8
 T cells speciﬁc for the wild-type and G357S escape vari-
ant epitopes, limiting the ability of the escape variant to con-
tinuously stimulate and expand CD8
 T cells speciﬁc for the
wild-type epitope and allowing for the recruitment of variant
epitope-speciﬁc CD8
 T cells utilizing distinct TCRs.
The analysis of statistical associations between sequence
polymorphisms within the p24 Gag349–359 A11-AK11 epitope
and HLA-A11 using data from the Western Australian HIV
Cohort Study, a cohort mainly (	75%) composed of HIV-1
clade B-infected individuals (35), showed that the G357Sm u -
tation occurs frequently on the population level in individuals
expressing this allele. Indeed, the HLA-A11-AK11G357S es-
cape variant was signiﬁcantly more frequently recognized in
HLA-A11-expressing individuals during chronic infection than
the wild-type variant, and the autologous virus in ﬁve out of
these eight chronically infected study subjects for whom viral
sequences were available harbored the HLA-A11-AK11G357S
escape variant. This is in striking contrast to the signiﬁcantly
lower frequency of the G357S variant in the sequences pub-
lished in the Los Alamos HIV-1 Database (25% G357S versus
71% G357 wild type; P  0.001). These data suggest that indi-
viduals expressing HLA-A11 frequently mount CD8
 T-cell
responses against a common HLA-A11-restricted escape vari-
ant in HIV-1 Gag. Further studies are needed to determine
whether this ability of HLA-A11-restricted CD8
 T cells to
have a “second chance” to target the evolving virus may at least
partially account for the association of the HLA-A11 allele
with slower disease progression in HIV-1 (36), the only
HLA-A allele that has been shown to be associated with a
protective effect on HIV-1 disease progression to date.
Reports on both HIV-1 and SIV infections suggest that viral
escape from virus-speciﬁc CD8
 T-cell responses can dramat-
ically compromise immune control (6, 8, 14, 21). Current
HIV-1 vaccine strategies do not adequately address this im-
portant limitation. However, recent data illustrate that the
simultaneous delivery of both wild-type and variant forms of an
immunodominant CD8
 T-cell epitope in mice was able to
avoid both T-cell antagonism and original antigenic sin (46).
Together with the data presented here, this suggests that si-
multaneous delivery of wild-type sequences and TCR escape
variant sequences of HIV-1-speciﬁc CD8
 T-cell epitopes may
represent an effective approach to inducing broadly reactive
CD8
 T-cell responses against multiple variant forms of a
CD8
 T-cell epitope to prevent viral escape.
Taken together, these studies demonstrate the ability of the
immune system to generate de novo CD8
 T-cell responses to
CTL escape variants in the context of chronic HIV-1 infection.
These data are of relevance for vaccine design, as priming of
both wild-type- and variant-speciﬁc CD8
 T-cell responses will
at the same time provide broad coverage against potential
circulating variants and protect against the emergence of es-
12958 ALLEN ET AL. J. VIROL.
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 cape variants that could be associated with the failure of vac-
cine-mediated protection.
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